<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_JHEPR100113 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEfx1 jpg ?><?FILEmmc1 pdf ?><?FILEmmc2 pdf ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">JHEP Rep</journal-id><journal-id journal-id-type="iso-abbrev">JHEP Rep</journal-id><journal-title-group><journal-title>JHEP Reports</journal-title></journal-title-group><issn pub-type="epub">2589-5559</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7128473</article-id><article-id pub-id-type="publisher-id">S2589-5559(20)30047-1</article-id><article-id pub-id-type="doi">10.1016/j.jhepr.2020.100113</article-id><article-id pub-id-type="publisher-id">100113</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Boettler</surname><given-names>Tobias</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Newsome</surname><given-names>Philip N.</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Mondelli</surname><given-names>Mario U.</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Maticic</surname><given-names>Mojca</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Cordero</surname><given-names>Elisa</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Cornberg</surname><given-names>Markus</given-names></name><xref rid="aff8" ref-type="aff">8</xref><xref rid="aff9" ref-type="aff">9</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Berg</surname><given-names>Thomas</given-names></name><email>Thomas.Berg@medizin.uni-leipzig.de</email><xref rid="aff10" ref-type="aff">10</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine II, Medical Center &#x02013; University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany</aff><aff id="aff2"><label>2</label>National Institute for Health Research, Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK</aff><aff id="aff3"><label>3</label>Centre for Liver &#x00026; Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK</aff><aff id="aff4"><label>4</label>Division of Infectious Diseases and Immunology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy</aff><aff id="aff5"><label>5</label>Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Slovenia</aff><aff id="aff6"><label>6</label>Faculty of Medicine, University of Ljubljana, Slovenia</aff><aff id="aff7"><label>7</label>Department of Medicine, University of Seville, Clinical Unit of Infectious Diseases University Hospital Virgen del Rocio, Institute of Biomedicine, Sevilla, CSIC, Spain</aff><aff id="aff8"><label>8</label>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany</aff><aff id="aff9"><label>9</label>Centre for Individualised Infection Medicine (CIIM), Hannover, Germany</aff><aff id="aff10"><label>10</label>Division of Hepatology, Clinic and Polyclinic for Gastroenterology, Hepatology, Infectious Diseases, and Pneumology, University Hospital Leipzig, Leipzig, Germany</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Address: University Hospital Leipzig, Department of Internal Medicine, Liebigstra&#x000df;e 18, D-04103 Leipzig, Germany; Tel.: +49 341/97-12200, fax: +49 341/97-12209. <email>Thomas.Berg@medizin.uni-leipzig.de</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>02</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>02</day><month>4</month><year>2020</year></pub-date><volume>2</volume><issue>3</issue><elocation-id>100113</elocation-id><history><date date-type="received"><day>25</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>31</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>31</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention.</p></abstract><kwd-group id="kwrds0010"><title>Abbreviations</title><kwd>ACE2, angiotensin-converting enzyme 2</kwd><kwd>ACE-I, angiotensin-converting enzyme inhibitor</kwd><kwd>ACLF, acute-on-chronic liver failure</kwd><kwd>ALT, alanine aminotransferase</kwd><kwd>AST, aspartate aminotransferase</kwd><kwd>COVID-19, coronavirus disease 2019</kwd><kwd>EGD, esophagogastroduodenoscopy</kwd><kwd>ERC, endoscopic retrograde cholangiography</kwd><kwd>HCC, hepatocellular carcinoma</kwd><kwd>MELD, model for end-stage liver disease</kwd><kwd>NAFLD, non-alcoholic fatty liver disease</kwd><kwd>NASH, non-alcoholic steatohepatitis</kwd><kwd>NUC, nucleoside analogue</kwd><kwd>PIs, protease inhibitors</kwd><kwd>RdRp, RNA-dependent RNA polymerase</kwd><kwd>SARS-CoV-2, severe acute respiratory syndrome coronavirus 2</kwd><kwd>ULN, upper limit of normal</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Coronavirus disease 2019 (COVID-19) is caused by the recently identified coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms associated with COVID-19 are mostly fever, tiredness and dry cough. Some patients also develop symptoms including shortness of breath, aches, nasal congestion, sore throat, anosmia and&#x000a0;ageusia. Nausea, vomiting and diarrhoea occur less frequently.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> While symptoms remain mild throughout the course of infection in the majority of patients, older patients were identified to be at higher risk of a fatal disease course, with hypertension, diabetes and coronary heart disease being the most frequent comorbidities in these cohorts.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref></p></sec><sec id="sec2"><title>COVID-19 and the liver</title><p id="p0015">While pre-existing liver disease is not specifically listed in the published cohort studies, elevated alanine aminotransferase (ALT) levels, reduced platelet counts and reduced albumin levels at the time of admission have been associated with higher mortality,<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> although not all of these alterations are independent risk factors. It remains unclear at this time whether these laboratory test alterations are a sign for pre-existing liver diseases in patients with a more severe course of infection, whether they rather reflect liver damage caused by the virus itself, or whether they mirror a severe inflammatory response (hypoalbuminemia) with disseminated intravascular coagulation (thrombocytopenia). Possibly, patients with advanced chronic liver disease are at increased risk of infection due to cirrhosis-associated immune dysfunction.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> The same could be true for patients after liver transplantation and possibly those with autoimmune liver diseases who receive immunosuppressive therapies.</p><p id="p0020">However, currently, there are only limited data available linking underlying liver diseases with the course of SARS-CoV-2 infection and there are many open questions (<xref rid="tbox1" ref-type="boxed-text">Box 1</xref>). Chronic hepatitis B virus infection for example, which is more prevalent in China than Europe, does not appear to affect the outcome of COVID-19.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> In addition, although there is no proof for this assumption, immunosuppression may even provide some protection from immunopathology, which appears to contribute to lung damage in cases with more severe manifestations of the disease.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> These may be associated with a macrophage activation syndrome in the context of a hyperinflammatory syndrome characterised by a cytokine storm with multi-organ failure.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> On the other hand, systemic viral infections are often associated with transient elevations of transaminases which may reflect general immune activation or inflammation caused by circulating cytokines without compromising liver function, a phenomenon called &#x0201c;bystander hepatitis&#x0201d;. This may also be the case in patients with COVID-19 where liver failure has not been specifically reported, even in the most severe and fatal courses of disease.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> However, signs of liver dysfunction may occur in critically ill patients with COVID-19,<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> as reviewed in.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Whether patients with cirrhosis and COVID-19 are at increased risk of decompensation or development of acute-on-chronic liver failure (ACLF), as has been shown for influenza infection,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> remains to be determined. SARS-CoV-2 may also directly infect liver cells as the receptor of the virus, angiotensin-converting enzyme 2 (ACE2),<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> has been shown to be expressed on cholangiocytes,<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> which may explain cases of viral shedding into the faeces.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> How far observations from Asian cohorts can be transferred to European populations remains to be determined, but it appears unlikely that SARS-CoV-2 infection causes liver damage to an amount that substantially contributes to the overall disease burden.<boxed-text id="tbox1"><label>Box 1</label><caption><title>Open questions for liver-related basic/translational research regarding COVID-19.</title></caption><p id="p0695"><fig id="undfig1"><graphic xlink:href="fx1"/></fig> ACLF, acute-on-chronic liver failure; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus&#x000a0;2.</p></boxed-text></p><p id="p0025">Aside from the direct implications of liver disease on the course of COVID-19 or vice versa, there are several additional aspects that require attention. The current pandemic and the amount of available information &#x02013; including misinformation and rumours &#x02013; result in uncertainties and concerns among patients but also healthcare providers. While the threat that COVID-19 poses should not be underestimated, it remains important to maintain care of patients with chronic liver disease and to identify potential ways to prioritise care of these patients in times of limited healthcare resources.</p></sec><sec id="sec3"><title>Considerations for patients with chronic liver disease and patients after liver transplantation</title><p id="p0030">The recommendations provided here address the specific characteristics of patients with liver disease and are meant to provide additional guidance for the care of these patients. General recommendations and guidelines with regards to prevention, diagnosis and treatment of COVID-19 from local authorities should be adhered to.</p></sec><sec id="sec4"><title>Outpatient care</title><p id="p0035">The management and surveillance of patients with advanced liver disease and those receiving immunosuppressive treatment is often performed in larger units or centres. These institutions, however, are currently also COVID-19 hotspots, thus, potentially putting outpatients with chronic liver diseases at risk of nosocomial infections. In addition, hospital staffs face challenges such as long working hours and even reduced staffing because of COVID-19 quarantining. Therefore, several factors have to be considered by hepatologists who provide care for these vulnerable patients. Clearly, prioritisation criteria need to be defined for outpatient contacts. The general and specific recommendations provided here (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>) cannot comprehensively cover all patient cohorts and are not backed up by datasets. Moreover, the precise management of these patients strongly depends on the local COVID-19 burden. In case of COVID-19 in patients with more advanced chronic liver disease, we recommend admission for inpatient care depending on the presence of certain risk factors, which is discussed in more detail in a separate section.<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Flow chart for the prioritisation of patient care in patients with chronic liver disease.</p><p>The individual management of these patients strongly depends on the local COVID-19 burden and officially implemented rules and regulations. In some countries and areas, maintenance of standard care might not be able and transplantation activities might be reduced. COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; SARS-CoV-2, severe acute respiratory syndrome coronavirus&#x000a0;2.</p></caption><graphic xlink:href="gr1"/></fig></p></sec><sec id="sec5"><title>Reduction of direct exposure</title><p id="p0040">Physical distancing has been suggested and/or officially implemented in multiple countries across the globe to prevent dissemination of SARS-CoV-2. This measure aims to prevent a rapid increase in SARS-CoV-2 infections in the general population with the overall goal of minimising the number of patients with a severe course of COVID-19 at any one time, enabling healthcare providers to maintain medical/intensive care of these patients. At the same time, vulnerable patient cohorts should be protected from individuals with potential SARS-CoV-2 exposure or infection. Thus, in these patients, the benefits of maintaining patient care have to be weighed against the risk of infection. These considerations require adaption of standard operating procedures for outpatient care, including remodelling of waiting areas to allow sufficient distance between patients, reduction of waiting times and encouraging patients to wait outside wherever possible and eventually be contacted by phone. In addition, exposure to medical staff should be minimised wherever possible.</p><p id="p0045">Face-to-face contact is the basis for the physician-patient relationships and allows physicians to quickly assess the overall condition of the patient. However, due to the amount of individual contacts, physicians are at risk of infection and subsequently also dissemination of the virus. Thus, it seems appropriate to also limit the amount of face-to-face contacts for patients at risk of a more severe course of infection. Technical solutions are available to enable remote physician-patient interactions and their benefits have already been discussed in the context of the COVID-19 pandemic.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> Health authorities should be urged to equip hospitals with such systems not only to attend to COVID-19 patients who stay in quarantine at home but also to care for patients that need to be protected from a potentially harmful infection and guide them through the pandemic, explaining the future treatment/management strategies/plan and provide advice concerning general prevention measures. The&#x000a0;current pandemic clearly underlines the importance of making these technical solutions available to health care providers in order to be better prepared for situations like these in the future.</p></sec><sec id="sec6"><title>Patients with compensated liver disease</title><sec id="sec6.1"><title>General considerations</title><p id="p0050"><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0055">Visits to specialised centres can be postponed.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0060">Use telemedicine or visits by phone wherever possible.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0065">Routine laboratory testing can be performed locally, <italic>e.g.</italic> through primary care physician, and its frequency needs careful individual risk-benefit considerations.</p></list-item></list></p></sec><sec id="sec6.2"><title>Specific considerations</title><p id="p0070"><list list-type="simple" id="ulist0015"><list-item id="u0025"><label>&#x02022;</label><p id="p0075">Chronic viral hepatitis does not appear to increase the risk of a severe course of COVID-19.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Use telemedicine/local laboratory testing for follow-up visits in patients under antiviral therapy, send follow-up-prescriptions by mail.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p0080">Patients with non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH) may suffer from metabolic comorbidities such as diabetes, hypertension and obesity putting them at increased risk of a severe course of COVID-19.</p></list-item><list-item id="u0035"><label>&#x02022;</label><p id="p0085">In patients with autoimmune liver disease, we currently advise against reducing immunosuppressive therapy. Reductions should only be considered under special circumstances (<italic>e.g.</italic> medication-induced lymphopenia, or bacterial/fungal superinfection in case of severe COVID-19) after consultation of a specialist.</p></list-item><list-item id="u0040"><label>&#x02022;</label><p id="p0090">Emphasis on the importance of vaccination for <italic>Streptococcus pneumoniae</italic> and influenza.</p></list-item><list-item id="u0045"><label>&#x02022;</label><p id="p0095">In patients with compensated cirrhosis, consider delaying hepatocellular carcinoma (HCC) surveillance and screening for varices. Non-invasive risk assessment for the presence of varices should be applied for stratification (thrombocyte count or Baveno VI).<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> See also section on &#x0201c;<xref rid="sec10" ref-type="sec">liver-related diagnostic procedures</xref>&#x0201d;.</p></list-item></list></p></sec></sec><sec id="sec7"><title>Patients with decompensated liver disease</title><sec id="sec7.1"><title>General considerations</title><p id="p0100"><list list-type="simple" id="ulist0020"><list-item id="u0050"><label>&#x02022;</label><p id="p0105">Care should be maintained according to guidelines but consider minimal exposure to medical staff, by using telemedicine/visits by phone wherever possible/required to avoid admission.</p></list-item><list-item id="u0055"><label>&#x02022;</label><p id="p0110">Listing for transplantation should be restricted to patients with poor short-term prognosis including those with acute/acute-on-chronic liver failure (ALF/ACLF), high model for end-stage liver disease (MELD) score (including exceptional MELDs) and HCC at the upper limits of the Milan criteria, as transplantation activities/organ donations will likely be reduced in many countries and areas.</p></list-item><list-item id="u0060"><label>&#x02022;</label><p id="p0115">Reducing the in-hospital liver transplant evaluation program to the strictly necessary is recommended to shorten the in-hospital stay and also reduce the number of consultations in other departments/clinics (<italic>i.e.</italic> ophthalmologic, dermatologic, dental, neurologic consultations can be done in local outpatient settings).</p></list-item><list-item id="u0065"><label>&#x02022;</label><p id="p0120">Emphasis on the importance of vaccination for <italic>Streptococcus pneumoniae</italic> and influenza.</p></list-item><list-item id="u0070"><label>&#x02022;</label><p id="p0125">Guidelines on prophylaxis of spontaneous bacterial peritonitis and hepatic encephalopathy should be closely followed to prevent decompensation and avoid admission.</p></list-item><list-item id="u0075"><label>&#x02022;</label><p id="p0130">Include testing for SARS-CoV-2 in patients with acute decompensation or ACLF.</p></list-item></list></p></sec><sec id="sec7.2"><title>Specific considerations for patients actively listed for transplantation</title><p id="p0135"><list list-type="simple" id="ulist0025"><list-item id="u0080"><label>&#x02022;</label><p id="p0140">SARS-CoV-2 routine testing should be performed before transplantation in both donors and recipients, acknowledging that negative testing cannot completely rule out infection.</p></list-item><list-item id="u0085"><label>&#x02022;</label><p id="p0145">Consent for diagnostic and therapeutic procedures related to&#x000a0;transplantation should include the potential risk of nosocomial COVID-19.</p></list-item><list-item id="u0090"><label>&#x02022;</label><p id="p0150">Living-donor transplantations should be considered on a case-by-case basis.</p></list-item></list></p></sec></sec><sec id="sec8"><title>Patients with hepatocellular carcinoma</title><p id="p0155"><list list-type="simple" id="ulist0030"><list-item id="u0095"><label>&#x02022;</label><p id="p0160">Care should be maintained according to guidelines including continuing systemic treatments and evaluation for liver transplantation, but consider minimal exposure to medical staff, by using telemedicine/visits by phone wherever possible/required to avoid admission.</p></list-item><list-item id="u0100"><label>&#x02022;</label><p id="p0165">In case of COVID-19, early admission is recommended. See also section on &#x0201c;<xref rid="sec12" ref-type="sec">inpatient care</xref>&#x0201d;.</p></list-item></list></p></sec><sec id="sec9"><title>Patients after liver transplantation</title><p id="p0170"><list list-type="simple" id="ulist0035"><list-item id="u0105"><label>&#x02022;</label><p id="p0175">Maintain care according to guidelines, but consider minimal exposure to medical staff, by using telemedicine/visits by phone wherever possible/required to avoid admission.</p></list-item><list-item id="u0110"><label>&#x02022;</label><p id="p0180">Emphasis on the importance of vaccination for <italic>Streptococcus pneumoniae</italic> and influenza.</p></list-item><list-item id="u0115"><label>&#x02022;</label><p id="p0185">In stable patients: perform local laboratory testing (including drug levels).</p></list-item><list-item id="u0120"><label>&#x02022;</label><p id="p0190">We currently advise against reduction of immunosuppressive therapy. Reduction should only be considered under special circumstances (<italic>e.g.</italic> medication-induced lymphopenia, or bacterial/fungal superinfection in case of severe COVID-19) after consultation of a specialist.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></p></list-item></list></p></sec><sec id="sec10"><title>Liver-related diagnostic procedures</title><sec id="sec10.1"><title>Endoscopy</title><p id="p0195"><italic>Patients without COVID-19:</italic> Depending on available resources, screening for varices by esophagogastroduodenoscopy (EGD) should be reserved for patients at risk of variceal bleeding, such as patients with a history of variceal bleeding or signs of significant portal hypertension (ascites, thrombocyte count &#x0003c;100,000/&#x003bc;l). Non-invasive risk assessment for the presence of varices should be applied for stratification (thrombocyte count or Baveno VI).</p><p id="p0200">Endoscopic retrograde cholangiography (ERC) for dilatation or stent replacement in patients after liver transplantation or patients with primary sclerosing cholangitis should be performed after careful individual risk-benefit considerations, including risk for nosocomial SARS-CoV-2 infection depending on local COVID-19 burden.</p><p id="p0205"><italic>Patients with COVID-19:</italic> Endoscopic procedures are associated with an increased risk of disseminating SARS-CoV-2. During EGD or ERC, spreading of virus-containing droplets can occur. In addition, shedding of the virus in the faeces increases the risk of dissemination during colonoscopy. Thus, indications for endoscopic procedures in patients with COVID-19 should be limited to emergencies such as gastrointestinal bleeding, bacterial cholangitis or other life-threatening conditions.</p></sec><sec id="sec10.2"><title>Ultrasound (HCC surveillance)</title><p id="p0210"><italic>Patients without COVID-19:</italic> HCC surveillance can be deferred based on available resources (including availability of therapeutic options in case of HCC diagnosis) at the centre and the individual risk assessment. Patients with increased risk, such as patients with elevated alpha-fetoprotein levels, advanced cirrhosis, chronic hepatitis B, NASH/diabetes <italic>etc.</italic>, may be prioritised if resources are limited.</p><p id="p0215"><italic>Patients with COVID-19:</italic> HCC surveillance should be deferred until after recovery.</p></sec><sec id="sec10.3"><title>Liver biopsy</title><p id="p0220"><italic>Patients without COVID-19:</italic> Recommendations strongly depend on the local COVID-19 burden and the individual indication for histological assessment.</p><p id="p0225">Biopsy should be deferred in patients with<list list-type="simple" id="ulist0040"><list-item id="u0125"><label>&#x02022;</label><p id="p0230">NAFLD or chronic viral hepatitis (for grading/staging)</p></list-item><list-item id="u0130"><label>&#x02022;</label><p id="p0235">mildly elevated transaminases (<italic>e.g.</italic> ALT &#x0003c;3&#x000d7; the upper limit of normal [ULN]) of unknown aetiology</p></list-item></list></p><p id="p0240">Biopsy should be performed in patients with<list list-type="simple" id="ulist0045"><list-item id="u0135"><label>&#x02022;</label><p id="p0245">strongly elevated transaminases (<italic>e.g.</italic> ALT &#x0003e;5&#x000d7; ULN) of unknown aetiology (in case of suspected autoimmune liver&#x000a0;disease, treatment without histological diagnosis can be considered based on individual risk-benefit considerations)</p></list-item><list-item id="u0140"><label>&#x02022;</label><p id="p0250">liver masses suspicious of malignancy</p></list-item></list></p><p id="p0255"><italic>Patients with COVID-19:</italic> Liver biopsy should be deferred in most patients as<list list-type="simple" id="ulist0050"><list-item id="u0145"><label>&#x02022;</label><p id="p0260">treatment/care for COVID-19 outweighs diagnosis of co-existing liver disease</p></list-item><list-item id="u0150"><label>&#x02022;</label><p id="p0265">systemic inflammation associated with COVID-19 will obscure aetiology-specific histologic characteristics</p></list-item><list-item id="u0155"><label>&#x02022;</label><p id="p0270">liver biopsy may represent a risk for viral transmission (although the virus has so far not been detected in liver tissue, the expression of its receptor on cholangiocytes suggests that the virus might be present in the liver as well).</p></list-item></list></p></sec></sec><sec id="sec11"><title>Collaboration with local health care providers and primary care physicians</title><p id="p0275">The necessity to reduce travel and limit visits to specialised centres is a challenge for liver disease patients and local health care providers alike. In order to facilitate decentralised care for&#x000a0;these patients, close collaborations between specialised hepatologists and local health care providers is required. This pertains to several factors such as communication of immunosuppressive target levels in patients after liver transplantation, management of patients with severe ALT elevations of unknown aetiologies and others. Thus, we recommend that specialised centres provide easily accessible contact information for local health care providers to facilitate fast and uncomplicated collaboration for the benefit of patients with liver diseases.</p></sec><sec id="sec12"><title>Inpatient care</title><p id="p0280">Many patients with chronic liver disease will continue to require inpatient care during the COVID-19 crisis for decompensation, cholangitis, rejection or other complications. General measures to prevent SARS-CoV-2 exposure and infection will be of utmost importance for these patients. Depending on the local infrastructure, implementation of COVID-19-clean wards or hospitals is warranted. However, based on the local COVID-19-burden, a sharp separation of &#x0201c;clean&#x0201d; and &#x0201c;dirty&#x0201d; wards/hospitals may not be sustainable, although recent evidence provides somewhat reassuring data regarding the absence of environmental contamination with SARS-CoV-2 RNA of inanimate surfaces outside patient rooms.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Wherever possible, patients with chronic liver disease requiring inpatient care for non-COVID-19 causes should be admitted to COVID-19-clean wards or hospitals. As these institutions may not be able to provide specialised hepatology-care, similar to our recommendations on outpatient care, we recommend that specialised centres provide easily accessible contact information to facilitate immediate hepatology consultations.</p><p id="p0285">However, due to the contagiousness of the virus, patients with underlying liver disease will become infected and will subsequently require inpatient care for COVID-19. With regards to nosocomial-infections, recent observations from Spain that compared patient characteristics between patients with community-acquired influenza and nosocomial-acquired influenza could not detect a significant difference between these cohorts with regards to underlying chronic liver disease.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Whether these observations will also hold up in the context of the COVID-19 pandemic remains to be proven. Until further evidence emerges, we recommend that patients with chronic liver disease and COVID-19 are admitted for inpatient care if they have additional risk factors for a more severe COVID-19 course like hypertension, diabetes or obesity, cirrhosis, HCC or a post-transplant status.</p></sec><sec id="sec13"><title>Treatment considerations for COVID-19</title><p id="p0290">Although there are currently no drugs approved for SARS-CoV-2, several repurposed drugs have been tested in recent weeks and many of them are still under investigation (see <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>).<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> Remdesivir acts as an adenosine-analogue that induces RNA chain termination and was initially developed as an antiviral agent against Ebola.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> It has recently been shown to inhibit a clinical isolate of SARS-CoV-2 <italic>in&#x000a0;vitro</italic><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> and to reduce disease severity of the related MERS-CoV-infection in a non-human primate model <italic>in&#x000a0;vivo</italic>.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> In addition, several reports have suggested clinical efficacy in patients suffering from COVID-19.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Clinical trials are ongoing to further evaluate efficacy in affected patients. Although ritonavir-boosted lopinavir showed some antiviral effect on SARS-CoV-2 <italic>in&#x000a0;vitro</italic>, a recently published clinical trial in patients with severe COVID-19 showed no effect <italic>in&#x000a0;vivo</italic> compared to no treatment.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Other drugs currently under&#x000a0;evaluation include chloroquine phosphate or hydroxychloroquine.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Chloroquine has shown antiviral efficacy against SARS-CoV-2 <italic>in&#x000a0;vitro</italic> through interference with the ACE2-receptor mediated endocytosis and is widely used in the treatment of patients with severe COVID-19 as monotherapy, but also in combination with azithromycin.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref> The administration of any of these compounds to infected patients will remain an individual decision as efficacy and optimal timing remain to be clarified. However, with regards to patients with chronic liver disease, possible adverse events have to be kept in mind. This is particularly important with respect to drug-interactions in patients with certain immunosuppressive therapies where drug levels of cyclosporine, tacrolimus, sirolimus or everolimus will have to be closely monitored. In addition, patients with impaired liver function are at high risk of drug toxicities, <italic>i.e.</italic> in patients with Child-Pugh B/C cirrhosis. <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref> summarises some considerations with regards to potential toxicities in these patients. It is also important to stress that all the drugs currently under investigation are not approved for SARS-CoV-2. However, given that early initiation of antiviral therapy is known to blunt the course of influenza, it is reasonable to assume that early treatment initiation might also be beneficial to prevent severe pneumonia in COVID-19. Thus, in patients with liver disease and risk factors for a severe course of the disease, we recommend inclusion into early antiviral treatment programmes or clinical trials that might be active at different centres.<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Selected repurposed drugs that have been suggested/discussed for the treatment of COVID-19 and considerations for patients with liver disease or after liver transplantation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drug</th><th>Mechanism of action, rationale for COVID-19</th><th>Considerations for patients with liver diseases or after liver transplantation</th></tr></thead><tbody><tr><td>Remdesivir</td><td><list list-type="simple" id="ulist0065"><list-item id="u0195"><label>&#x02022;</label><p id="p0365">NUC/viral RNA polymerase inhibitor (completed phase III for Ebola treatment)</p></list-item><list-item id="u0200"><label>&#x02022;</label><p id="p0370">Inhibits SARS-CoV-2 <italic>in&#x000a0;vitro</italic><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></p></list-item><list-item id="u0205"><label>&#x02022;</label><p id="p0375">Case reports with COVID-19<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0070"><list-item id="u0210"><label>&#x02022;</label><p id="p0380">No relevant drug-interactions expected<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref></p></list-item><list-item id="u0215"><label>&#x02022;</label><p id="p0385">No experience in liver cirrhosis but a NUC might be safer than other drug classes based on experience with NUCs in chronic hepatitis B and C</p></list-item><list-item id="u0220"><label>&#x02022;</label><p id="p0390">Liver toxicity (&#x02191;ALT) possible</p></list-item></list></td></tr><tr><td>Chloroquine/Hydroxychloroquine<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> &#x000b1; azithromycin</td><td><list list-type="simple" id="ulist0075"><list-item id="u0225"><label>&#x02022;</label><p id="p0395">Interference with the cellular receptor ACE2<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></p></list-item><list-item id="u0230"><label>&#x02022;</label><p id="p0400">Endosomal acidification fusion inhibitor</p></list-item><list-item id="u0235"><label>&#x02022;</label><p id="p0405">Generally used for treatment of malaria and amoebiasis</p></list-item><list-item id="u0240"><label>&#x02022;</label><p id="p0410"><italic>In&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> data<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0080"><list-item id="u0245"><label>&#x02022;</label><p id="p0415">Exclude G6PD deficiency before application</p></list-item><list-item id="u0250"><label>&#x02022;</label><p id="p0420">Drug-interactions with immunosuppressive drugs: close monitoring of drug level is required for cyclosporine, tacrolimus, sirolimus, everolimus<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref></p></list-item><list-item id="u0255"><label>&#x02022;</label><p id="p0425">Hydroxychloroquine therapy has not been associated with ALT abnormalities and is an extremely rare cause of clinically apparent acute liver injury (LiverTox).</p></list-item></list></td></tr><tr><td>Lopinavir/ritonavir</td><td><list list-type="simple" id="ulist0085"><list-item id="u0260"><label>&#x02022;</label><p id="p0430">Lopinavir/ritonavir are approved PIs for HIV</p></list-item><list-item id="u0265"><label>&#x02022;</label><p id="p0435"><italic>In&#x000a0;vitro</italic> data, experience in patients with SARS, case reports with COVID-19<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref></p></list-item><list-item id="u0270"><label>&#x02022;</label><p id="p0440">No proven efficacy <italic>in&#x000a0;vivo</italic> in severe COVID-19<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref></p></list-item><list-item id="u0275"><label>&#x02022;</label><p id="p0445">Many centres have discontinued its use</p></list-item></list></td><td><list list-type="simple" id="ulist0090"><list-item id="u0280"><label>&#x02022;</label><p id="p0450">Known and well-studied drug-interactions with immunosuppressive drugs. mTOR inhibitors (sirolimus, everolimus) should not be co-administered, close monitoring of drug level are required for calcineurin-inhibitors (cyclosporin, tacrolimus)<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref></p></list-item><list-item id="u0285"><label>&#x02022;</label><p id="p0455">Data for patients with liver cirrhosis exist<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref></p></list-item><list-item id="u0290"><label>&#x02022;</label><p id="p0460">The risk of lopinavir-associated hepatotoxicity in patients with very advanced liver disease is low</p></list-item><list-item id="u0295"><label>&#x02022;</label><p id="p0465">Based on experience with PIs in HCV, patients with decompensated cirrhosis should not be treated</p></list-item></list></td></tr><tr><td>Tocilizumab</td><td><list list-type="simple" id="ulist0095"><list-item id="u0300"><label>&#x02022;</label><p id="p0470">Humanised mAb targeting interleukin-6 receptor</p></list-item><list-item id="u0305"><label>&#x02022;</label><p id="p0475">Treat cytokine release syndrome observed in COVID-19<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0100"><list-item id="u0310"><label>&#x02022;</label><p id="p0480">ALT elevations are frequent but clinically apparent&#x000a0;liver&#x000a0;injury&#x000a0;with jaundice seem to be rare<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref></p></list-item><list-item id="u0315"><label>&#x02022;</label><p id="p0485">Patients with decompensated cirrhosis should not be treated</p></list-item><list-item id="u0320"><label>&#x02022;</label><p id="p0490">Consider risk of HBV reactivation<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></p></list-item></list></td></tr><tr><td>Methylprednisolone (steroids)</td><td><list list-type="simple" id="ulist0105"><list-item id="u0325"><label>&#x02022;</label><p id="p0495">Corticosteroids bind nuclear receptors to dampen proinflammatory cytokines</p></list-item><list-item id="u0330"><label>&#x02022;</label><p id="p0500">Mostly used in patients with septic shock</p></list-item><list-item id="u0335"><label>&#x02022;</label><p id="p0505">Currently NOT recommended by WHO<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0110"><list-item id="u0340"><label>&#x02022;</label><p id="p0510">The risk of other infections (<italic>e.g.</italic> SBP) and viral shedding may increase in patents with decompensated liver cirrhosis</p></list-item><list-item id="u0345"><label>&#x02022;</label><p id="p0515">Consider antimicrobial prophylaxis</p></list-item><list-item id="u0350"><label>&#x02022;</label><p id="p0520">Consider risk of HBV reactivation</p></list-item></list></td></tr><tr><td>Convalescent plasma</td><td><list list-type="simple" id="ulist0115"><list-item id="u0355"><label>&#x02022;</label><p id="p0525">Case reports with COVID-19<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0120"><list-item id="u0360"><label>&#x02022;</label><p id="p0530">No experience in patients with chronic liver disease</p></list-item></list></td></tr><tr><td>Umifenovir (Arbidol)<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td><td><list list-type="simple" id="ulist0125"><list-item id="u0365"><label>&#x02022;</label><p id="p0535">May inhibit viral entry into target cells and stimulate the immune response, used to treat influenza in some countries<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0130"><list-item id="u0370"><label>&#x02022;</label><p id="p0540">Possible drug interactions between arbidol and CYP3A4 inhibitors and inducers<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref></p></list-item><list-item id="u0375"><label>&#x02022;</label><p id="p0545">Potentially metabolised in liver and intestines in humans. Caution in patients with liver cirrhosis</p></list-item></list></td></tr><tr><td>Favipiravir/favilavir<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td><td><list list-type="simple" id="ulist0135"><list-item id="u0380"><label>&#x02022;</label><p id="p0550">Guanine analogue, RNA-dependent RNA polymerase (RdRp)- inhibitor, approved for influenza in Japan</p></list-item><list-item id="u0385"><label>&#x02022;</label><p id="p0555">Preliminary results from a study with 80 COVID-19 patients<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0140"><list-item id="u0390"><label>&#x02022;</label><p id="p0560">Metabolised by aldehyde oxidase and xanthine oxidase. CYP450 isoenzymes are not involved in the metabolism</p></list-item><list-item id="u0395"><label>&#x02022;</label><p id="p0565">Elevation of ALT and AST possible.</p></list-item><list-item id="u0400"><label>&#x02022;</label><p id="p0570">No data in cirrhosis available</p></list-item></list></td></tr><tr><td>Sofosbuvir<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref><break/>maybe combination with ribavirin</td><td><list list-type="simple" id="ulist0145"><list-item id="u0405"><label>&#x02022;</label><p id="p0575">Nucleotide analogue, RdRp-inhibitor</p></list-item><list-item id="u0410"><label>&#x02022;</label><p id="p0580">Approved for treatment of chronic hepatitis C</p></list-item><list-item id="u0415"><label>&#x02022;</label><p id="p0585"><italic>In&#x000a0;vitro</italic> data show binding to SARS-CoV-2 RdRp<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0150"><list-item id="u0420"><label>&#x02022;</label><p id="p0590">Good experience in patients with chronic hepatitis C including patients with decompensated cirrhosis</p></list-item><list-item id="u0425"><label>&#x02022;</label><p id="p0595">For drug-interaction details see<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref></p></list-item><list-item id="u0430"><label>&#x02022;</label><p id="p0600">Ribavirin may cause severe haemolytic anaemia</p></list-item></list></td></tr><tr><td>Baricitinib<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td><td><list list-type="simple" id="ulist0155"><list-item id="u0435"><label>&#x02022;</label><p id="p0605">Janus kinase inhibitor, might interrupt endocytosis of the virus and intracellular assembly of virus particles<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref></p></list-item><list-item id="u0440"><label>&#x02022;</label><p id="p0610">Could affect both inflammation and cellular viral entry</p></list-item></list></td><td><list list-type="simple" id="ulist0160"><list-item id="u0445"><label>&#x02022;</label><p id="p0615">Associated with transient and usually mild elevations of ALT<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></p></list-item><list-item id="u0450"><label>&#x02022;</label><p id="p0620">Patients with decompensated cirrhosis should not be treated</p></list-item></list></td></tr><tr><td>Camostat<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td><td><list list-type="simple" id="ulist0165"><list-item id="u0455"><label>&#x02022;</label><p id="p0625">Blocks serine protease TMPRSS2 <italic>in&#x000a0;vitro</italic> which is required for S protein priming<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></p></list-item><list-item id="u0460"><label>&#x02022;</label><p id="p0630">Licensed in Japan for treatment of chronic pancreatitis</p></list-item></list></td><td><list list-type="simple" id="ulist0170"><list-item id="u0465"><label>&#x02022;</label><p id="p0635">Patients with chronic viral hepatitis and cirrhosis are excluded from clinical trial for chronic pancreatitis.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref></p></list-item><list-item id="u0470"><label>&#x02022;</label><p id="p0640">Drug-interactions unknown</p></list-item></list></td></tr><tr><td>Emapalumab<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td><td><list list-type="simple" id="ulist0175"><list-item id="u0475"><label>&#x02022;</label><p id="p0645">mAb targeting interferon-gamma</p></list-item><list-item id="u0480"><label>&#x02022;</label><p id="p0650">Treat cytokine release syndrome observed in COVID-19<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref></p></list-item><list-item id="u0485"><label>&#x02022;</label><p id="p0655">Approved for haemophagocytic lymphohistiocytosis</p></list-item><list-item id="u0490"><label>&#x02022;</label><p id="p0660">Clinical trial for COVID-19 planned<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0180"><list-item id="u0495"><label>&#x02022;</label><p id="p0665">Associated with mild and transient ALT elevations typically arising a few weeks after start of treatment</p></list-item><list-item id="u0500"><label>&#x02022;</label><p id="p0670">Risk of reactivation of tuberculosis, pneumocystis jirovecii, herpes zoster</p></list-item><list-item id="u0505"><label>&#x02022;</label><p id="p0675">Risk of HBV reactivation may be lower</p></list-item></list></td></tr><tr><td>Anakinra<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td><td><list list-type="simple" id="ulist0185"><list-item id="u0510"><label>&#x02022;</label><p id="p0680">Interleukin 1 receptor antagonist</p></list-item><list-item id="u0515"><label>&#x02022;</label><p id="p0685">Clinical trial for COVID-19 planned<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></p></list-item></list></td><td><list list-type="simple" id="ulist0190"><list-item id="u0520"><label>&#x02022;</label><p id="p0690">Minimal hepatic metabolism</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>This list is not intended to give treatment recommendations. The evidence to use these drugs is low. Multiple RCTs for the above-mentioned drugs and some other drugs are ongoing in patients with SARS-CoV-2 infection.</p></fn><fn id="tspara0020"><p>ACE2, angiotensin-converting enzyme 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; NUC, nucleoside analogue; PIs, protease inhibitors; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome coronavirus&#x000a0;2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnlowast"><label>&#x02217;</label><p id="ntpara0010">These drugs are listed to include the most frequently discussed agents for COVID-19. These drugs may lack clinical efficacy, and some have been considered based on <italic>in&#x000a0;vitro</italic> observations or their mode of action.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec13.1"><title>General considerations for patients with chronic liver disease and COVID-19</title><p id="p0295"><list list-type="simple" id="ulist0055"><list-item id="u0160"><label>&#x02022;</label><p id="p0300">Consider early admission according to the presence of additional risk factors and inclusion in clinical trials and (experimental) antiviral therapy of COVID-19 following local guidelines (see <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref> for guidance with regards to CLD)</p></list-item><list-item id="u0165"><label>&#x02022;</label><p id="p0305">Prevent acetaminophen overdosing (2&#x02013;3 g/day is considered safe in patients with cirrhosis without active alcohol consumption<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref>)</p></list-item><list-item id="u0170"><label>&#x02022;</label><p id="p0310">Do not administer non-steroidal anti-inflammatory drugs in patients with cirrhosis and portal hypertension<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref></p></list-item><list-item id="u0175"><label>&#x02022;</label><p id="p0315">See also section on &#x0201c;<xref rid="sec10" ref-type="sec">liver-related diagnostic procedures</xref>&#x0201d; for recommendations on endoscopy, HCC surveillance and liver biopsy</p></list-item></list></p></sec><sec id="sec13.2"><title>Specific considerations for patients with chronic liver disease and COVID-19</title><p id="p0320"><list list-type="simple" id="ulist0060"><list-item id="u0180"><label>&#x02022;</label><p id="p0325">In patients with decompensated cirrhosis, treatment for cirrhosis-associated complications such as portal hypertension, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis <italic>etc.</italic> should be continued.</p></list-item><list-item id="u0185"><label>&#x02022;</label><p id="p0330">In patients with HCC, locoregional therapies should be postponed whenever possible and immune-checkpoint inhibitor therapy temporarily withdrawn. The decision on&#x000a0;whether to continue (reduced dose) kinase inhibitors in non-severe COVID-19 should be taken on a case-by-case basis.</p></list-item><list-item id="u0190"><label>&#x02022;</label><p id="p0335">In patients after liver transplantation, dose adjustment of calceurin- and/or mTOR- inhibitors might be required depending on the antiviral therapy initiated (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>).</p></list-item></list></p></sec></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p id="p0340">Dr Berg reports grants, personal fees and non-financial support from <funding-source id="gs1">Gilead</funding-source>. Dr Boettler reports consultancy fees from Gilead. Dr Cornberg reports personal fees from Gilead. All other authors report no conflicts of interest.</p><p id="p0345">Please refer to the accompanying <xref rid="appsec1" ref-type="sec">ICMJE disclosure</xref> forms for further details.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.J.</given-names></name><name><surname>Ni</surname><given-names>Z.Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.H.</given-names></name><name><surname>Ou</surname><given-names>C.Q.</given-names></name><name><surname>He</surname><given-names>J.X.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N&#x000a0;Engl J Med</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><issue>10229</issue><year>2020</year><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Gou</surname><given-names>X.</given-names></name><name><surname>Pu</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name></person-group><article-title>Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis</article-title><source>Int J Infect Dis</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Albillos</surname><given-names>A.</given-names></name><name><surname>Lario</surname><given-names>M.</given-names></name><name><surname>&#x000c1;lvarez-Mon</surname><given-names>M.</given-names></name></person-group><article-title>Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance</article-title><source>J&#x000a0;Hepatol</source><volume>61</volume><year>2014</year><fpage>1385</fpage><lpage>1396</lpage><pub-id pub-id-type="pmid">25135860</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir Med</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Geng</surname><given-names>M.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name></person-group><article-title>Molecular immune pathogenesis and diagnosis of COVID-19</article-title><source>J&#x000a0;Pharm Anal</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P.</given-names></name><name><surname>McAuley</surname><given-names>D.F.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Tattersall</surname><given-names>R.S.</given-names></name><name><surname>Manson</surname><given-names>J.J.</given-names></name></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><volume>395</volume><issue>10229</issue><year>2020</year><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Shu</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>Ja</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title><source>Lancet Respir Med</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>F.-S.</given-names></name></person-group><article-title>Liver injury in COVID-19: management and challenges</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name></person-group><article-title>Liver injury during highly pathogenic human coronavirus infections</article-title><source>Liver Int</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Sch&#x000fc;tte</surname><given-names>A.</given-names></name><name><surname>Ciesek</surname><given-names>S.</given-names></name><name><surname>Wedemeyer</surname><given-names>H.</given-names></name><name><surname>Lange</surname><given-names>C.M.</given-names></name></person-group><article-title>Influenza virus infection as precipitating event of acute-on-chronic liver failure</article-title><source>J&#x000a0;Hepatol</source><volume>70</volume><year>2019</year><fpage>797</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">30635243</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Park</surname><given-names>Y.-J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A.T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Ke</surname><given-names>A.</given-names></name></person-group><article-title>Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection</article-title><source>bioRxiv</source><year>2020</year></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Zhong</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Dan</surname><given-names>H.</given-names></name><name><surname>Zeng</surname><given-names>X.</given-names></name></person-group><article-title>High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa</article-title><source>Int J Oral Sci</source><volume>12</volume><year>2020</year><fpage>8</fpage><pub-id pub-id-type="pmid">32094336</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>C.</given-names></name><name><surname>Kaushal</surname><given-names>S.</given-names></name><name><surname>Yeo</surname><given-names>D.</given-names></name></person-group><article-title>Enteric involvement of coronaviruses: is faecal&#x02013;oral transmission of SARS-CoV-2 possible?</article-title><source>Lancet Gastroenterol Hepatol</source><volume>5</volume><year>2020</year><fpage>335</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">32087098</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>COVID-19: gastrointestinal manifestations and potential fecal-oral transmission</article-title><source>Gastroenterology</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Hollander</surname><given-names>J.E.</given-names></name><name><surname>Carr</surname><given-names>B.G.</given-names></name></person-group><article-title>Virtually perfect? Telemedicine for Covid-19</article-title><source>N&#x000a0;Engl J Med</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Maurice</surname><given-names>J.B.</given-names></name><name><surname>Brodkin</surname><given-names>E.</given-names></name><name><surname>Arnold</surname><given-names>F.</given-names></name><name><surname>Navaratnam</surname><given-names>A.</given-names></name><name><surname>Paine</surname><given-names>H.</given-names></name><name><surname>Khawar</surname><given-names>S.</given-names></name></person-group><article-title>Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices</article-title><source>J&#x000a0;Hepatol</source><volume>65</volume><year>2016</year><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">27388923</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name></person-group><article-title>Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression</article-title><source>Am J Transplant</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Colaneri</surname><given-names>M.</given-names></name><name><surname>Seminari</surname><given-names>E.</given-names></name><name><surname>Piralla</surname><given-names>A.</given-names></name><name><surname>Zuccaro</surname><given-names>V.</given-names></name><name><surname>Filippo</surname><given-names>A.D.</given-names></name><name><surname>Baldanti</surname><given-names>F.</given-names></name></person-group><article-title>Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy</article-title><source>J&#x000a0;Hosp Infect</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Godoy</surname><given-names>P.</given-names></name><name><surname>Torner</surname><given-names>N.</given-names></name><name><surname>Soldevila</surname><given-names>N.</given-names></name><name><surname>Rius</surname><given-names>C.</given-names></name><name><surname>Jane</surname><given-names>M.</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>A.</given-names></name></person-group><article-title>Hospital-acquired influenza infections detected by a surveillance system over six seasons, from 2010/2011 to 2015/2016</article-title><source>BMC Infect Dis</source><volume>20</volume><year>2020</year><fpage>80</fpage><pub-id pub-id-type="pmid">31992207</pub-id></element-citation></ref><ref id="bib22"><label>22</label><mixed-citation publication-type="other" id="oref22">Harrison C. Coronavirus puts drug repurposing on the fast track. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41587-020-00003-1" id="intref0015a">https://www.nature.com/articles/d41587-020-00003-1</ext-link>. [Accessed 12 March 2020].</mixed-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>T.K.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Lo</surname><given-names>M.K.</given-names></name><name><surname>Ray</surname><given-names>A.S.</given-names></name><name><surname>Mackman</surname><given-names>R.L.</given-names></name><name><surname>Soloveva</surname><given-names>V.</given-names></name></person-group><article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</article-title><source>Nature</source><volume>531</volume><year>2016</year><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">26934220</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in&#x000a0;vitro</article-title><source>Cell Res</source><volume>30</volume><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Cronin</surname><given-names>J.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Thomas</surname><given-names>T.</given-names></name></person-group><article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title><source>Proc Natl Acad Sci</source><volume>117</volume><issue>12</issue><year>2020</year><fpage>6771</fpage><lpage>6776</lpage><pub-id pub-id-type="pmid">32054787</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M.L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K.H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>New Engl J Med</source><volume>382</volume><year>2020</year><fpage>929</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Won</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>A.J.</given-names></name></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat Commun</source><volume>11</volume><year>2020</year><fpage>222</fpage><pub-id pub-id-type="pmid">31924756</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name></person-group><article-title>A&#x000a0;trial of lopinavir&#x02013;ritonavir in adults hospitalized with severe Covid-19</article-title><source>N&#x000a0;Engl J Med</source><year>2020</year></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source>Biosci Trends</source><volume>14</volume><issue>1</issue><year>2020</year><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">32074550</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title><source>Nat Rev Drug Discov</source><volume>19</volume><year>2020</year><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">32127666</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</article-title><source>Drug Discoveries Ther</source><volume>14</volume><year>2020</year><fpage>58</fpage><lpage>60</lpage></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name><name><surname>Hoang</surname><given-names>V.T.</given-names></name><name><surname>Meddeb</surname><given-names>L.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2020</year><fpage>105949</fpage><pub-id pub-id-type="pmid">32205204</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Chandok</surname><given-names>N.</given-names></name><name><surname>Watt</surname><given-names>K.D.S.</given-names></name></person-group><article-title>Pain management in the cirrhotic patient: the clinical challenge</article-title><source>Mayo Clinic Proc</source><volume>85</volume><year>2010</year><fpage>451</fpage><lpage>458</lpage></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="book" id="sref34"><source>COVID-19 Drug interactions</source><year>2020</year><comment>Available from:</comment><ext-link ext-link-type="uri" xlink:href="http://www.covid19-druginteractions.org/" id="intref0020">http://www.covid19-druginteractions.org/</ext-link></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><article-title>[Expert consensus on chloroquine phosphate for the treatment of novel&#x000a0;coronavirus pneumonia]</article-title><source>Zhonghua Jie He He Hu Xi Za Z</source><volume>43</volume><year>2020</year><fpage>E019</fpage></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Al-Bari</surname><given-names>M.A.A.</given-names></name></person-group><article-title>Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases</article-title><source>Pharmacol Res Perspect</source><volume>5</volume><year>2017</year><fpage>e00293</fpage><pub-id pub-id-type="pmid">28596841</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Young</surname><given-names>B.E.</given-names></name><name><surname>Ong</surname><given-names>S.W.X.</given-names></name><name><surname>Kalimuddin</surname><given-names>S.</given-names></name><name><surname>Low</surname><given-names>J.G.</given-names></name><name><surname>Tan</surname><given-names>S.Y.</given-names></name><name><surname>Loh</surname><given-names>J.</given-names></name></person-group><article-title>Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore</article-title><source>JAMA</source><year>2020</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Casado</surname><given-names>J.L.</given-names></name><name><surname>Del Palacio</surname><given-names>M.</given-names></name><name><surname>Moya</surname><given-names>J.</given-names></name><name><surname>Rodriguez</surname><given-names>J.M.</given-names></name><name><surname>Moreno</surname><given-names>A.</given-names></name><name><surname>Perez-El&#x000ed;as</surname><given-names>M.J.</given-names></name></person-group><article-title>Safety and pharmacokinetics of lopinavir in HIV/HCV coinfected&#x000a0;patients with advanced liver disease</article-title><source>HIV Clin Trials</source><volume>12</volume><year>2011</year><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">22180521</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Genovese</surname><given-names>M.C.</given-names></name><name><surname>Kremer</surname><given-names>J.M.</given-names></name><name><surname>van Vollenhoven</surname><given-names>R.F.</given-names></name><name><surname>Alten</surname><given-names>R.</given-names></name><name><surname>Scali</surname><given-names>J.J.</given-names></name><name><surname>Kelman</surname><given-names>A.</given-names></name></person-group><article-title>Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis</article-title><source>Arthritis Rheumatol</source><volume>69</volume><year>2017</year><fpage>1751</fpage><lpage>1761</lpage><pub-id pub-id-type="pmid">28597609</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.-F.</given-names></name><name><surname>Mo</surname><given-names>Y.-Q.</given-names></name><name><surname>Jing</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>J.-D.</given-names></name><name><surname>Zheng</surname><given-names>D.-H.</given-names></name><name><surname>Dai</surname><given-names>L.</given-names></name></person-group><article-title>Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation</article-title><source>Int J Rheum Dis</source><volume>20</volume><year>2017</year><fpage>859</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">28160426</pub-id></element-citation></ref><ref id="bib41"><label>41</label><mixed-citation publication-type="other" id="oref22a">WHO. Clinical management of severe acute respiratory infection (SARI)&#x000a0;when COVID-19 disease is suspected. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected" id="intref0025">https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected</ext-link>. [Accessed 18 March 2020].</mixed-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>P.</given-names></name><name><surname>Zhong</surname><given-names>D.</given-names></name><name><surname>Yu</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans</article-title><source>Antimicrob Agents Chemother</source><volume>57</volume><year>2013</year><fpage>1743</fpage><lpage>1755</lpage><pub-id pub-id-type="pmid">23357765</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>A.A.</given-names></name></person-group><article-title>Anti-HCV, nucleotide inhibitors, repurposing against COVID-19</article-title><source>Life Sci</source><volume>248</volume><year>2020</year><fpage>117477</fpage><pub-id pub-id-type="pmid">32119961</pub-id></element-citation></ref><ref id="bib45"><label>45</label><mixed-citation publication-type="other" id="oref22x">HEP Drug interactions. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.hep-druginteractions.org/" id="intref0030">https://www.hep-druginteractions.org/</ext-link>. [Accessed 20 March 2020].</mixed-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P.</given-names></name><name><surname>Griffin</surname><given-names>I.</given-names></name><name><surname>Tucker</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Oechsle</surname><given-names>O.</given-names></name><name><surname>Phelan</surname><given-names>A.</given-names></name></person-group><article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>e30</fpage><lpage>e31</lpage><pub-id pub-id-type="pmid">32032529</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Markham</surname><given-names>A.</given-names></name></person-group><article-title>Baricitinib: first global approval</article-title><source>Drugs</source><volume>77</volume><year>2017</year><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">28290136</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>M.L.</given-names></name><name><surname>Nuttall</surname><given-names>J.</given-names></name><name><surname>Hart</surname><given-names>P.A.</given-names></name><collab>on behalf of the TIT</collab></person-group><article-title>A&#x000a0;phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)</article-title><source>Trials</source><volume>20</volume><year>2019</year><fpage>501</fpage><pub-id pub-id-type="pmid">31412955</pub-id></element-citation></ref><ref id="bib50"><label>50</label><mixed-citation publication-type="other" id="oref50x">Press release on planned clinical trials to evaluate anakinra and emapalumab in COVID-19. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.sobi.com/en/press-releases/sobi-initiate-clinical-study-evaluate-whether-anakinra-and-emapalumab-may-relieve" id="intref0035">https://www.sobi.com/en/press-releases/sobi-initiate-clinical-study-evaluate-whether-anakinra-and-emapalumab-may-relieve</ext-link>. [Accessed 30 March 2020].</mixed-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary data</title><p id="p0355"><supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary information</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>disclosures.pdf</title></caption><media xlink:href="mmc2.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgement</title><p>We thank Benjamin Maasoumy for critically reviewing the manuscript and providing valuable comments.</p></ack><fn-group><fn id="d31e618"><p id="ntpara0015">Author names in bold designate shared co-first authorship</p></fn><fn id="appsec2" fn-type="supplementary-material"><p id="p0360">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhepr.2020.100113" id="intref0010">https://doi.org/10.1016/j.jhepr.2020.100113</ext-link>.</p></fn></fn-group></back></article>